Gamma-Hydroxybutyric acid (GHB) occurs endogenously in the brain where it is thought to be a neurotransmitter. GHB is used clinically for treating alcoholism and narcolepsy and is used non-medicinally, both as a primary drug of abuse (presumably because of its sedative/hypnotic effects) and as a sedating agent in unsuspecting victims (e.g., """"""""date rate drug""""""""). Despite GHB having been described more than 30 years ago and despite its widespread use, both medicinally and non-medicinally, relatively little is known about the mechanism that mediates the various effects of GHB. A GHB-associated binding site has been reported, although it is not known whether this site mediates the abuse- related effects of GHB. The paucity of information on the mechanism(s) of action of GHB results from a very limited set of relevant compounds that are available for studying this neurobiologic system and the absence of pharmacologically selective and validated neurochemical and behavioral procedures for characterizing the effects of GHB and related compounds. To that end, the studies proposed in this application will first characterize the receptor binding and behavioral effects of GHB and related compounds. Second, these studies will design and synthesize new compounds for studying the pharmacology of GHB. The working hypothesis of these multidisciplinary studies is that the behavioral effects of GHB are due to its actions on specific sites in brain that are not related to either GABAA or GABAB receptors. Studies under Specific Aim I will design and synthesize potent and selective agonists and antagonists for GHB receptors.
Specific Aim II will characterize the binding of GHB and other compounds, including compounds that are synthesized under Specific Aim I, to specific sites in rat brain that have been characterized by our group with [3H]NCS-382. The functional consequences of GHB binding will be examined under Specific Aim III, including a characterization of the effects of GHB and other compounds on schedule-controlled behavior and an evaluation of discriminative stimulus effects of GHB. These systematic characterizations of the binding and behavioral effects of GHB and the development of newly-synthesized compounds for GHB receptors will provide important new information regarding the mechanisms that mediate effects of GHB and related compounds.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA014986-02
Application #
6523556
Study Section
Special Emphasis Panel (ZDA1-RXL-E (08))
Program Officer
Lin, Geraline
Project Start
2001-09-26
Project End
2004-07-31
Budget Start
2002-09-10
Budget End
2003-07-31
Support Year
2
Fiscal Year
2002
Total Cost
$331,848
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Pharmacology
Type
Other Domestic Higher Education
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Carter, Lawrence P; Koek, Wouter; France, Charles P (2009) Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther 121:100-14
Ticku, Maharaj K; Mehta, Ashok K (2008) Characterization and pharmacology of the GHB receptor. Ann N Y Acad Sci 1139:374-85
Carter, Lawrence P; Chen, Weibin; Coop, Andrew et al. (2006) Discriminative stimulus effects of GHB and GABA(B) agonists are differentially attenuated by CGP35348. Eur J Pharmacol 538:85-93
Mehta, Ashok K; Gould, Georgianna G; Gupta, Maneesh et al. (2006) Succinate semialdehyde dehydrogenase deficiency does not down-regulate gamma-hydroxybutyric acid binding sites in the mouse brain. Mol Genet Metab 88:86-9
Koek, Wouter; Chen, Weibin; Mercer, Susan L et al. (2006) Discriminative stimulus effects of gamma-hydroxybutyrate: role of training dose. J Pharmacol Exp Ther 317:409-17
Carter, Lawrence P; Koek, Wouter; France, Charles P (2006) Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats. Eur J Neurosci 24:2595-600
Carter, Lawrence P; Wu, Huifang; Chen, Weibin et al. (2005) Novel gamma-hydroxybutyric acid (GHB) analogs share some, but not all, of the behavioral effects of GHB and GABAB receptor agonists. J Pharmacol Exp Ther 313:1314-23
Chen, Weibin; Wu, Huifang; Hernandez, R Jason et al. (2005) Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands. Bioorg Med Chem Lett 15:3201-2
Koek, Wouter; Carter, Lawrence P; Lamb, R J et al. (2005) Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam. J Pharmacol Exp Ther 314:170-9
Sevak, Rajkumar J; Koek, Wouter; France, Charles P (2005) Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy. Eur J Pharmacol 517:64-7

Showing the most recent 10 out of 22 publications